These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 25636238

  • 1. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
    Bailly F, Virlogeux V, Dufour C, Pradat P, Hézode C, Larrey D, Alric L, Samuel D, Bourlière M, Métivier S, Zarski JP, Fontaine H, Loustaud-Ratti V, Serfaty L, Bronowicki JP, Carrat F, Zoulim F, CUPIC Study Group.
    Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):443-50. PubMed ID: 25636238
    [Abstract] [Full Text] [Related]

  • 2. The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.
    Boursier J, Ducancelle A, Vergniol J, Veillon P, Moal V, Dufour C, Bronowicki JP, Larrey D, Hézode C, Zoulim F, Fontaine H, Canva V, Poynard T, Allam S, De Lédinghen V, ANRS CO20 CUPIC Study Group.
    J Viral Hepat; 2015 Dec; 22(12):1002-10. PubMed ID: 26216230
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
    Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP, CUPIC Study Group.
    Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Triple therapy with boceprevir or telaprevir for prior HCV non-responders.
    Asselah T.
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):455-62. PubMed ID: 23199504
    [Abstract] [Full Text] [Related]

  • 6. Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients.
    Arends JE, van der Meer JT, Posthouwer D, Kortmann W, Brinkman K, van Assen S, Smit C, van der Valk M, van der Ende M, Schinkel J, Reiss P, Richter C, Hoepelman AI, Stichting HIV Monitoring/Nederlandse Vereniging van HIV Behandelaren Hepatitis Working Group, ATHENA national observational HIV cohort.
    Neth J Med; 2015 Aug; 73(7):324-30. PubMed ID: 26314715
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.
    Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, Shvachko VA, Pauly MP, Chua J, Monto A, Terrault NA.
    Aliment Pharmacol Ther; 2014 May; 39(10):1213-24. PubMed ID: 24654657
    [Abstract] [Full Text] [Related]

  • 10. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
    Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP, CUPIC Study Group.
    J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker JP, Molina JM, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group.
    Clin Infect Dis; 2014 Dec 15; 59(12):1768-76. PubMed ID: 25139963
    [Abstract] [Full Text] [Related]

  • 16. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
    Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, Bonhomme-Faivre L, Roque-Afonso AM, Vittecoq D, Samuel D, Taburet AM, Duclos-Vallée JC.
    AIDS; 2015 Jan 02; 29(1):53-8. PubMed ID: 25387314
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
    Shiffman ML, Esteban R.
    Liver Int; 2012 Feb 02; 32 Suppl 1():54-60. PubMed ID: 22212573
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Future treatment of patients with HCV cirrhosis.
    Bourlière M, Khaloun A, Wartelle-Bladou C, Oules V, Portal I, Benali S, Adhoute X, Castellani P.
    Liver Int; 2012 Feb 02; 32 Suppl 1():113-9. PubMed ID: 22212581
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.